1G2L

FACTOR XA INHIBITOR COMPLEX

Summary for 1G2L

• Entry DOI: 10.2210/pdb1g2l/pdb
• Descriptor: COAGULATION FACTOR X, CALCIUM ION, [(1-{2[(4-CARBAMIMIDOYL-PHENYLAMINO)-METHYL]-1-METHYL-1H-BENZOIMIDAZOL-5-YL}-CYCLOPROPYL)-PYRIDIN-2-YL-METHYLENEAMINOOXY]-ACETIC ACID ETHYL ESTER, ... (5 entities in total)
• Functional Keywords: blood coagulation, factor xa, inhibitor complexes, serine proteinase, blood coagulation cascade, hydrolase
• Biological source: Homo sapiens (human); More
• Cellular location: Secreted: P00742 P00742
• Total number of polymer chains: 2
• Total formula weight: 37411.33

Authors

Nar, H. (deposition date: 2000-10-20, release date: 2001-10-20, Last modification date: 2011-07-13)

Primary citation

Nar, H.,Bauer, M.,Schmid, A.,Stassen, J.M.,Wienen, W.,Priepke, H.W.,Kauffmann, I.K.,Ries, U.J.,Hauel, N.H.
Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Structure, 9:29-38, 2001

PubMed Abstract: A major current focus of pharmaceutical research is the development of selective inhibitors of the blood coagulation enzymes thrombin or factor Xa to be used as orally bioavailable anticoagulant drugs in thromboembolic disorders and in the prevention of venous and arterial thrombosis. Simultaneous direct inhibition of thrombin and factor Xa by synthetic proteinase inhibitors as a novel approach to antithrombotic therapy could result in potent anticoagulants with improved pharmacological properties.

PubMed: 11342132
DOI: 10.1016/S0969-2126(00)00551-7

Experimental method

X-RAY DIFFRACTION (1.9 Å)